TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11762418
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (e.g., Rituxan, Mylotarg, Campath)
Study: 11762418
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies as monotherapy or in combination with conventional chemotherapies
Study: 11762418
Drug: Engineered antibodies
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engineered antibodies
Study: 11762418
Drug: Antibody engineering
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody engineering
Study: 7829762
Drug: brofaromine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: brofaromine 150 mg daily (n = 111)
Study: 7829762
Drug: brofaromine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: brofaromine 150 mg daily
Study: 27998964
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg daily plus gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle
Study: 27998964
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle
Study: 26165360
Drug: Continuous 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 3.0 intradermal non-absorbable polypropylene suture (Prolene™ 0, Ethicon Inc. Somerville, New Jersey, USA)
Study: 23715754
Drug: GFT505 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFT505 (80 mg/day)
Study: 16574037
Drug: P‐ERMS once
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐ERMS once daily in AM or PM for a 4‐week treatment period
Study: 9402690
Drug: CsA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA with MMF (1.0 g bid)
Study: 9402690
Drug: CsA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA with MMF (1.5 g bid)
Study: 29638148
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg IV infusion twice daily for up to 14 days
Study: 29638148
Drug: Cimetidine 50
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 50 mg/h continuous IV infusion following an initial bolus of 300 mg for up to 14 days
Study: 30182671
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Levocetirizine and Montelukast
Study: 23535873
Drug: Beta-alanine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (6.4 g · d(‐1) for 4 weeks)
Study: 20495586
Drug: Cervical interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical interlaminar epidural injections with 0.5% lidocaine (4 mL) mixed with 1 mL of non-particulate betamethasone
Study: 15985032
Drug: Ciclopirox 0.77%
Normalized name: CICLOPIROX 0.77% SUSP,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox 0.77% gel applied twice daily
Study: 15985032
Drug: Ciclopirox 0.77%
Normalized name: CICLOPIROX 0.77% SUSP,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox 0.77% gel applied once daily
Study: 12325402
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (two 40‐min sessions per week for 5 weeks)
Study: 7795096
Drug: TMP-SMZ (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMZ (640 mg/3,200 mg)
Study: 2343070
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg haloperidol
Study: 7000476
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg chenodeoxycholic acid (CDC)/day
Study: 7000476
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg chenodeoxycholic acid (CDC)/day
Study: 7000476
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg CDC/day (after 6 months for placebo patients)
Study: 26180108
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose target of 100‐140 mg/dL (n = 151)
Study: 26180108
Drug: Conservative glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative glucose target of 141‐180 mg/dL (n = 151)
Study: 24375220
Drug: Oral Targin
Normalized name: naloxone hydrochloride / oxycodone hydrochloride Extended Release Oral Tablet [Targiniq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Targin (oxycodone-hydrochloride and naloxone hydrochloride-dihydrate)
Study: 24375220
Drug: Patient-controlled IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled IV morphine
Study: 19900154
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Exercise and Pravastatin
Study: 10636271
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy for acute myocardial infarction (AMI)
Study: 8731641
Drug: Sodium picosulphate
Normalized name: Sodium Picosulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium picosulphate solution (Picolax)
Study: 8731641
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol bowel lavage solution (Klean Prep)
Study: 1413580
Drug: Drugs and
Normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs and graded walking
Study: 1413580
Drug: Drugs and
Normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs and low-effort bicycle exercise
Study: 4054193
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of original lipophilic beta-blocker
Study: 26795423
Drug: General practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner (GP) treatment as usual
Study: 24697877
Drug: L-NMMA (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (during atorvastatin and placebo treatment)
Study: 22332798
Drug: Metformin (achieved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (achieved glycemic control with HbA1c ≤ 8% for at least 2 months)
Study: 20009090
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day rimonabant
Study: 12795771
Drug: Alefacept 7.5
Normalized name: ALEFACEPT 7.5MG/VI INJ KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 7.5 mg IV
Study: 12795771
Drug: Alefacept 7.5
Normalized name: ALEFACEPT 7.5MG/VI INJ KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 7.5 mg IV (after second course)
Study: 10596705
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (500 microg b.i.d., for three weeks)
Study: 10596705
Drug: Nonsteroid medication
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroid medication (control group)
Study: 8739860
Drug: Oxy- and
Normalized name: Pur-Oxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxy- and xylometazoline nasal sprays
Study: 8739860
Drug: Topical vasoconstrictors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vasoconstrictors
Study: 8739860
Drug: Benzalkonium chloride
Normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzalkonium chloride in nasal decongestant solutions
Study: 1924660
Drug: Venlafaxine 25
Normalized name: venlafaxine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 25 mg t.i.d.
Study: 1924660
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg t.i.d.
Study: 1924660
Drug: Venlafaxine 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 125 mg t.i.d.
Study: 29426270
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (EvPO) 1000 mg, twice daily for 7 days
Study: 25450583
Drug: 100mg/day coQ10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/day coQ10 capsules
Study: 22189825
Drug: Antiglaucomatous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiglaucomatous therapy (various medications including metipranolol 0.3%, timolol 0.5%, dorzolamid, brinzolamid, brimonidine, bimatoprost, travoprost, and latanoprost)
Study: 22189825
Drug: Monotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy and dual therapy (two substances in one drug)
Study: 22189825
Drug: Prostaglandin agonists
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin agonists (PGA)
Study: 22189825
Drug: Timolol plus
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol plus brinzolamide (combined therapy)
Study: 20211296
Drug: Enteric-coated aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin, 100 mg/d
Study: 10368815
Drug: Flaxseed (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (5 g/day)
Study: 10368815
Drug: Flaxseed (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (10 g/day)
Study: 8768018
Drug: Mixed parenteral
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed parenteral and enteral nutrition
Study: 7045615
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy plus BCG
Study: 7045615
Drug: PPD conversion
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPD conversion from negative to positive during therapy
Study: 19460609
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration before CABG
Study: 19460609
Drug: No clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No clopidogrel administration before CABG (Control)
Study: 17089420
Drug: Behavioral Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Weight Loss Treatment (BWLT)
Study: 8758833
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (30 min daily for 10 days at points PC6, LI4, ST36, RN4 and symptomatic points bilaterally)
Study: 6985
Drug: Anxiety evocation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiety evocation during treatment
Study: 28586628
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) combined with supervised exercises
Study: 28586628
Drug: Sham Radial
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham Radial Extracorporeal Shock Wave Therapy combined with supervised exercises
Study: 28586628
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) in patients with calcification in rotator cuff
Study: 22011856
Drug: Soybean-treated group
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean-treated group (12.95 g of soy protein for 90 days)
Study: 16416230
Drug: Mesalamine (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (2.4 g/day; n = 9)
Study: 15477799
Drug: Statins (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (specific dosage and duration not mentioned)
Study: 16399214
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone releasing hormone (GHRH)
Study: 8012861
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (42 micrograms/nostril)
Study: 8012861
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (168 micrograms/nostril)
Study: 2557947
Drug: Pseudoephedrine 60
Normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 60 mg plus ibuprofen 200 mg
Study: 2557947
Drug: Pseudoephedrine 60
Normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 60 mg alone
Study: 1195153
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy (maintenance follow-up)
Study: 25893930
Drug: Lycopene 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene 35 mg, selenium 55 µg, and green tea catechins 600 mg
Study: 24090777
Drug: Prenatal exposure
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exposure to antiepileptic drugs (AED)
Study: 24090777
Drug: No AED
Approvals — FDA: no, EMA: no, PMDA: no
Description: No AED treatment during pregnancy
Study: 17140280
Drug: Zolmitriptan 2.5
Normalized name: zolmitriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 2.5 mg oral tablet
Study: 12830602
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 20 micrograms 2-hourly to a maximum of four doses (80 micrograms)
Study: 12830602
Drug: Dinoprostone 1
Normalized name: dinoprostone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone 1 mg inserted in the posterior fornix and repeated 6-hourly to a maximum of three doses
Study: 12830602
Drug: Misoprostol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (both oral and vaginal)
Study: 9125276
Drug: Transdermal Patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Patch (Dermestril 50, 4 mg E2, delivers 50 micrograms E2 daily)
Study: 9125276
Drug: Oral Tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet (2 mg micronized E2, daily administration)
Study: 28697253
Drug: Augment current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augment current treatment with bupropion (n=506)
Study: 22492518
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2-3)
Study: 24692475
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg/d)
Study: 22179601
Drug: Landiolol (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (group L, n = 32)
Study: 17364234
Drug: OSI-7904L 12
Normalized name: OSI-7904L
DrugBank: OSI-7904L (DB05457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSI-7904L 12 mg/m2 intravenously every 21 days
Study: 17364234
Drug: 5-FU/LV (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV (intravenous l-LV 200 mg/m2, bolus 5-FU 400 mg/m2 and a 46-h infusion of 5-FU 2,400 mg/m2) every 14 days
Study: 16291062
Drug: Ertapenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (1 g daily; n=295)
Study: 12122922
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of ketamine
Study: 12122922
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a weak opioid and an NMDA-receptor antagonist
Study: 8560901
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/day (LDL < 195 mg/dl) or 20 mg/day (LDL > 195 mg/dl)
Study: 3389862
Drug: 4 IU
Normalized name: Cholecalciferol/Vitamin E 14000 IU-34 IU Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU growth hormone three days a week (group 1)
Study: 3389862
Drug: 1 IU
Normalized name: factor VIII 1 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 IU twice daily six days a week (group 3)
Study: 28181206
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (Symfona® forte 120 mg) twice-daily for 6 months
Study: 21381497
Drug: Ultrasound-guided intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intra-articular injection of hyaluronic acid products
Study: 18156154
Drug: Robot-based hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-based hand motor therapy emphasizing intense active movement repetition, attention, speed, force, precision, and timing, including virtual reality games for 3 weeks.
Study: 18156154
Drug: Grasp task
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grasp task practiced during robotic therapy.
Study: 9484356
Drug: Anti-indigestion drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-indigestion drug use
Study: 8057411
Drug: Trazodone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (150 mg to 200 mg)
Study: 3246169
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg ceftriaxone (single dose)
Study: 3246169
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg ceftriaxone (3 consecutive days)
Study: 27384040
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) combined with conventional scaling and root planing (SRP)
Study: 22222052
Drug: IFN α-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN α-2a (180 μg once weekly) + weight-based RBV
Study: 22222052
Drug: IFN α-2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN α-2b (1.5 μg/kg once weekly) + weight-based RBV
Study: 23908086
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg/d)
Study: 16506273
Drug: Voglibose (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.6 mg/d)
Study: 10551687
Drug: Abciximab plus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab plus low-dose heparin
Study: 3056085
Drug: Fibraccel (50-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibraccel (50-ml infusions lasting 30 min each, started immediately after antagonism by protamine chloride, followed by subsequent 50-ml infusions every 4 h until 20 h after extracorporeal circulation)
Study: 3056085
Drug: Placebo infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions at corresponding times
Study: 30168511
Drug: Combined physiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined physiotherapy including treatment in the spa capsule (n=29)
Study: 30168511
Drug: Local vacuum
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local vacuum therapy (n=28)
Study: 30168511
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic stimulation therapy (n=29)
Study: 14574032
Drug: Pharmacologic antiarrhythmic
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic antiarrhythmic therapy
Study: 10225168
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg kg‐1
Study: 8903382
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg/d, 5 days per week) + UDCA (13-15 mg x kg(‐1) x day(‐1))
Study: 1864448
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day diclofenac potassium for 7 days
Study: 1864448
Drug: 1.2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/day ibuprofen
Study: 27083135
Drug: 1% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% dextrose in Ringer lactate (RL) at 10 ml·kg(‐1) ·h(‐1) (Group D1)
Study: 27083135
Drug: 2% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dextrose in Ringer lactate (RL) at 10 ml·kg(‐1) ·h(‐1) (Group D2)
Study: 27083135
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose in N/5 saline at 4 ml·kg(‐1) ·h(‐1) and replacement fluid with 6 ml·kg(‐1) ·h(‐1) of RL (Group D4)
Study: 25096822
Drug: Lactose solution
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose solution (25 g)
Study: 17617338
Drug: Single vendor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vendor implant selection
Study: 10497961
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone
Study: 2174320
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during hyperglycaemia
Study: 2174320
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion during hyperinsulinaemia with euglycemia or hyperglycaemia
Study: 7239110
Drug: Starch enemas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch enemas (10%; 1000 ml t.i.d.) plus neomycin tablets
Study: 7239110
Drug: Lactose enemas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose enemas (20%; 1000 ml t.i.d.) plus placebo tablets
Study: 7239110
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (starch enemas plus neomycin tablets)
Study: 7239110
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lactose enemas plus placebo tablets)
Study: 30709694
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no LED light irradiation)
Study: 29565642
Drug: MRI evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI evaluation for both treatments
Study: 25708531
Drug: Cal/BD ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal/BD ointment
Study: 11304721
Drug: 220 mg
Normalized name: urea 220 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 mg of naproxen sodium
Study: 11304721
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of diphenhydramine hydrochloride